Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
106.83
+4.32 (4.21%)
May 9, 2025, 1:49 PM - Market open
Ligand Pharmaceuticals Revenue
Ligand Pharmaceuticals had revenue of $45.33M in the quarter ending March 31, 2025, with 46.34% growth. This brings the company's revenue in the last twelve months to $181.49M, up 53.40% year-over-year. In the year 2024, Ligand Pharmaceuticals had annual revenue of $167.13M with 27.28% growth.
Revenue (ttm)
$181.49M
Revenue Growth
+53.40%
P/S Ratio
10.54
Revenue / Employee
$2,668,941
Employees
68
Market Cap
2.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 167.13M | 35.82M | 27.28% |
Dec 31, 2023 | 131.31M | -64.93M | -33.09% |
Dec 31, 2022 | 196.25M | -45.30M | -18.75% |
Dec 31, 2021 | 241.54M | 77.98M | 47.68% |
Dec 31, 2020 | 163.56M | 43.28M | 35.98% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LGND News
- 23 hours ago - Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Ligand Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 8 days ago - Ligand to Participate in May Investor Conferences - GlobeNewsWire
- 15 days ago - Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 - GlobeNewsWire
- 22 days ago - Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics - GlobeNewsWire
- 2 months ago - Ligand to Participate in March Investor Conferences - GlobeNewsWire
- 2 months ago - Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Ligand Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire